Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H
Department of Internal Medicine I, Division of Haematology and Blood Coagulation, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
Br J Haematol. 2001 Mar;112(3):783-6. doi: 10.1046/j.1365-2141.2001.02608.x.
Arsenic trioxide (As2O3) induces remission in a high proportion of patients with acute promyelocytic leukaemia (APL) via induction of apoptosis. Preliminary reports suggest that the apoptotic effect of As2O3 is not specific for APL but can also be observed in non-APL acute myeloid leukaemia (AML) cells, although these are less sensitive than APL cells. Ascorbic acid has recently been demonstrated to enhance the apoptotic effect of As2O3. We have therefore evaluated combined As2O3/ascorbic acid treatment in various clinical samples of AML. Our results indicate a significant synergistic effect of As2O3 and ascorbic acid, suggesting a possible future role of As2O3/ascorbic acid combination therapy in patients with AML.
三氧化二砷（As2O3）通过诱导凋亡使大部分急性早幼粒细胞白血病（APL）患者获得缓解。初步报告表明，As2O3的凋亡作用并非APL所特有，在非APL急性髓系白血病（AML）细胞中也可观察到，尽管这些细胞不如APL细胞敏感。最近已证实，维生素C可增强As2O3的凋亡作用。因此，我们评估了As2O3/维生素C联合治疗在AML各种临床样本中的效果。我们的结果表明，As2O3与维生素C具有显著的协同作用，提示As2O3/维生素C联合疗法未来可能在AML患者中发挥作用。
